moon

New Jersey was treated Sunday night to a look at the biggest supermooon the state has seen in more than 60 years. Thanks to the moon’s orbit, it appeared larger and brighter Sunday night than it normally does, and should be just as visible Monday night. 5 things to know about N.J.’s supermoon Though we generally…

Yahoo (YHOO) revenue and profit are expected to plunge when it reports Q2 results on Monday, but one analyst doesn’t rule out the possibility of the web portal walking away from takeover offers just the same.

Final bids for Yahoo’s core internet and advertising businesses are also due Monday, with Verizon Communications (VZ) in the hunt, along with a group led by Quicken Loans co-founder Dan Gilbert. Verizon would merge Yahoo with AOL, which it acquired in 2015. Gilbert’s group has the backing of Warren Buffett’s Berkshire Hathaway (BRKB).

The sales process has dragged on since March. Most reports have cited bids in a range of $4 billion to $6 billion for Yahoo’s core internet assets, real estate and patents. AT&T (T) and private equity firm PG Capital also might be in the mix.

Analysts polled by Thomson Reuters estimate that Yahoo’s Q2 revenue will fall 13% to $1.08 billion while EPS plummets 40% to 10 cents. While Yahoo seems in dire straits, its Asian investments may provide some leeway, says Robert Peck, an analyst at SunTrust Robinson Humphrey.

“At some price level, the board may feel it is better to simply spin off the core to shareholders in Read Full Article

Source: Technology – IBD

The drug industry’s Q2 earnings season launches next week with three of its biggest names, whose broad portfolios could give investors a preview of how the business in general is doing.

The big kahuna, Johnson & Johnson (JNJ), on Tuesday morning is expected to report 1% year-over-year sales growth, but a modest decline in EPS to $1.68 a share. The stock is trading near all-time highs after rising 20% for the year, due to “strong pharma trends, and flight to safety and yield,” wrote RBC Capital Markets analyst Glenn Novarro in his July 8 preview note.

Analysts are expecting another good quarter for J&J’s pharma business; Novarro wrote that based on prescription data from IMS Health (IMS), four of J&J’s biggest drugs — Remicade, Imbruvica, Invokana and Xarelto — will beat consensus. Credit Suisse analyst Vamil Divan, in his July 10 preview, lowered his estimates for Invokana while raising them for Remicade and Xarelto. But he said he was concerned about the entry of cheaper biosimilar versions of Remicade later this year. Pfizer‘s (PFE) Remicade biosimilar was approved by the FDA in April.


IBD’S TAKE: Most drug stocks have taken a pounding this year, but J&J has proved Read Full Article

Source: Technology – IBD

Netflix (NFLX) stock has struggled since the internet television network in April guided to disappointing subscriber growth for the second quarter.

Netflix stock rose 0.4% to 98.39 on Friday ahead of the company’s Q2 earnings report, set for Monday after the market close.

Shares are down 9% since Netflix reported Q1 results and gave its Q2 guidance on April 18. For the year to date, Netflix stock is down 14%.

So, expectations are muted for the company’s Q2 report.


IBD’s TAKE: Netflix has fallen out of favor with investors. It currently ranks No. 20 out of 21 stocks in IBD’s Leisure-Movies & Related industry group. For more information on Netflix stock, visit IBD Stock Checkup.


Netflix expects to add 500,000 new U.S. streaming subscribers in the June quarter, down from 900,000 in the year-earlier period. It is targeting 2 million new international streaming subscribers, vs. 2.37 million a year ago.

Analysts polled by Thomson Reuters expect Netflix to earn 2 cents a share on sales of $2.11 billion. A year earlier, Netflix earned 6 cents a share on sales of $1.64 billion. But earnings have taken a back seat to sales growth as the company has rapidly expanded Read Full Article

Source: Technology – IBD

Apple (AAPL) supplier Skyworks Solutions (SWKS) is expected late Thursday to report a sixth consecutive quarter of year-over-year declines in earnings. In its fiscal third-quarter report, Skyworks also is forecast to post sales that recovered minimally from the company’s slowest-ever growth period.

For fiscal Q3, the consensus of 24 analysts polled by Thomson Reuters models $750.2 million in sales, down 7% on a year-over-year basis vs. 2% growth in the prior quarter. But $1.21 earnings per share ex items would fall 10%.

Skyworks’ sales and EPS have both decelerated for five consecutive quarters. Like Apple’s other chip suppliers, Skyworks was tugged down in April on Apple’s first quarterly sales drop since 2003 and first-ever iPhone sales dip.

Unlike fellow Apple supplier Qualcomm (QCOM) — set to report its fiscal Q3 on Wednesday — analysts don’t expect a Q4 recovery for Skyworks. Wall Street’s model calls for a 6% decline in sales and a 7% decline in EPS in fiscal Q4.

Skyworks rivals Broadcom (AVGO) and Qorvo (QRVO) in supplying radio-frequency chips for Apple’s iPhones. But Broadcom recently gapped up with the $37 billion merger with the former Avago, and Qorvo is leading Skyworks in the carrier-aggregation Read Full Article

Source: Technology – IBD

Microsoft‘s (MSFT) path to growth is expected to take a detour with its fiscal fourth-quarter earnings report, due out after the close Tuesday.

Analysts polled by Thomson Reuters expect the software giant to earn 58 cents a share, down 3% year over year, on sales of $22.14 billion, down a fraction, in the June quarter.

It would mark the first decline in EPS in five quarters and the fourth drop in sales in the last five quarters.

Microsoft is transitioning from a company focused on client-server software to one focused on internet cloud computing services.

Since its last earnings report, Microsoft announced plans to buy professional network site LinkedIn (LNKD) for $26.2 billion. Plus, in May, Microsoft took a $950 million impairment and restructuring charge to streamline its smartphone business.

Microsoft stock dipped a fraction to 53.70 on Friday. It was the stock’s first down day in the last nine trading sessions.


IBD’s TAKE: Microsoft stock has climbed nine of the last 11 trading sessions since breaking through its 50-day moving average line on June 30. But Microsoft stock has a middling IBD Composite Rating of 42. For more stock analysis, consult the IBD Stock Checkup.


For Read Full Article

Source: Technology – IBD

The augmented-reality smartphone game “Pokemon Go” has become a global phenomenon with millions of people playing it in public parks, streets and shops.

It also has amused late-night comedians who have cracked many jokes at the expense of fans of the game.

The game is a joint venture of the Pokemon Company, which is 40%-owned by Nintendo (NTDOY), and Niantic, a spinout from Alphabet (GOOGL). Nintendo also is an investor in Niantic.

Among the comics making fun of “Pokemon Go” are Jimmy Fallon, Seth Meyers and Conan O’Brien. What follows is a summary of jokes those late-night talk-show hosts have made about the hit game.

Conan: According to the police, robbers have been ambushing people playing Pokemon Go by luring them to remote locations. The item most commonly reported stolen is any chance at a real adulthood.

Conan: The guy is going to be OK, but in California, a man playing Pokemon Go was stabbed. The man said, “It was terrifying, my lack of a life flashed before my eyes.”

Conan: The game Pokemon Go is actually making people visit remote, potentially dangerous areas. On the bright side, they finally found a way to get people to attend the Rio Olympics.

Conan: The Read Full Article

Source: Technology – IBD

Investment bank Barclays on Friday cut its price target on Apple (AAPL) stock for the third time in as many months ahead of the company’s June-quarter earnings report.

Barclays analyst Mark Moskowitz reiterated his overweight rating on Apple but trimmed his price target to 115 from 121. Apple was flat, near 99, in afternoon trading on the stock market today. Apple is scheduled to report fiscal third-quarter results on July 26.

“This is the third consecutive pre-earnings cut, which is becoming tedious,” Moskowitz said in a report. “The magnitude of the cut is a little bigger than the prior two. However, we think the stock could work after any post-earnings weakness, as the lead up to the iPhone 7 launch is not too far away.”


IBD’S TAKE: Apple has been a laggard on the stock market of late. The consumer electronics manufacturer has an IBD Composite Rating of 27, which puts it in the lower third of publicly traded companies in key metrics. More information on Apple is available on the IBD Stock Checkup page.


Moskowitz expects calendar 2017 to mark the start of a “mega (upgrade) cycle” with the iPhone 8 and its Read Full Article

Source: Technology – IBD